Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is conducting an open-label Phase 1 study titled ‘AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES.’ The study aims to assess the safety and effects of PF-08046037, alone or combined with sasanlimab, in treating advanced or metastatic malignancies such as non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, and pancreatic ductal adenocarcinoma. This research is significant as it targets difficult-to-treat cancers, potentially offering new therapeutic options.
The interventions being tested include PF-08046037, administered intravenously, and sasanlimab, given subcutaneously. These treatments are designed to explore dosage escalation, optimization, and expansion in patients whose cancers are not responding to current therapies.
The study is interventional, with a non-randomized, sequential model focusing on treatment. It involves no masking, meaning all participants and researchers know the treatments being administered. The primary purpose is to evaluate treatment efficacy and safety.
The study began on May 6, 2025, with its primary completion date yet to be determined. The latest update was submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This update may influence Pfizer’s stock performance positively, as successful trials could lead to new product approvals and market expansion. Investors should also consider the competitive landscape, as advancements in cancer treatment are highly competitive and rapidly evolving.
The study is currently recruiting, with further details available on the ClinicalTrials portal.